Retina

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

This research was a finalist in the 2020 Ophthalmology Times® Research Scholar Honoree Program.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

Study highlights extracellular matrix-related proteins expressed in PVR.

Clues to diagnosis from patient/family histories, examination techniques.

Trial shows treatment has acceptable safety profile, may improve visual function.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Novel treatments are now shifting paradigm in care of retinal diseases.

Retinal imaging tests are providing material to train and test decision-support systems.

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

Increased access is key to preventing disease progression in patients.

Visible-light optical coherence tomography proves valuable in studies.

Investigators find approach improved vision and visual fields in some patients.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Study results show that aflibercept-treated eyes are protected.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.

Option has a broader biologic effect for patients.

Worldwide increase in technologies for ophthalmic use is dramatic.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).